Monte Rosa Therapeutics, Inc. (GLUE)

NASDAQ: GLUE · Real-Time Price · USD

22.68

+1.12 (5.19%)

At close: Jul 30, 2026, 4:00 PM EDT

22.90

+0.22 (0.97%)

After-hours: Jul 30, 2026, 7:34 PM EDT

Monte Rosa Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	159.86	129.88	224.25	128.1	54.91	346.07
Short-Term Investments	506.36	247.22	147.9	104.31	207.91	-
Cash & Short-Term Investments	666.22	377.1	372.15	232.41	262.83	346.07
Cash Growth	104.32%	1.33%	60.12%	-11.57%	-24.05%	729.93%
Accounts Receivable	-	7	-	-	-	-
Other Receivables	4.61	4.6	0.17	0.51	7.66	-
Total Trade Receivables	4.61	11.6	0.17	0.51	7.66	-
Other Current Assets	6.72	4.48	5.12	3.29	5.4	2.6
Total Current Assets	677.55	393.19	377.44	236.21	275.89	348.67
Net Property, Plant & Equipment	53.1	50.37	56.31	62.61	61.91	12.33
Other Long-Term Assets	5.78	5.1	4.98	4.93	4.6	5.34
Total Assets	736.43	448.66	438.73	303.76	342.39	366.33

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Accounts Payable	7.9	3.55	17.22	11.15	7.86	6.56
Accrued Expenses	25.59	26.69	18.79	14.6	14.58	10.08
Current Portion of Leases	4.48	4.4	3.71	3.16	3.13	-
Unearned Revenue	33.06	29.57	117.23	17.68	-	-
Total Current Liabilities	71.04	64.21	156.95	46.59	25.57	16.64
Long-Term Leases	34.58	34.79	39	42.88	43.87	-
Other Long-Term Liabilities	108.9	116.6	19.85	35.04	1.53	2.18
Total Long-Term Liabilities	143.48	151.39	58.85	77.91	45.41	2.18
Total Liabilities	214.51	215.6	215.8	124.51	70.98	18.81

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Common Stock	0.01	0.01	0.01	0	0.01	0.01
Additional Paid-in Capital	1,048	714.09	664.87	547.86	503.7	471.57
Accumulated Other Comprehensive Income	-4.75	-3.83	-3.36	-2.72	-1.75	-2.02
Retained Earnings	-521.72	-477.21	-438.59	-365.89	-230.54	-122.04
Total Common Shareholders' Equity	521.92	233.06	222.94	179.25	271.41	347.52
Shareholders' Equity	521.92	233.06	222.94	179.25	271.41	347.52
Total Liabilities & Equity	736.43	448.66	438.73	303.76	342.39	366.33

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Total Debt	39.06	39.19	42.72	46.04	47	0
Net Cash (Debt)	627.16	337.91	329.43	186.37	215.83	346.07
Net Cash Growth	120.67%	2.57%	76.76%	-13.65%	-37.64%	729.93%
Net Cash Per Share	7.17	4.07	4.46	3.63	4.57	13.84
Book Value	521.92	233.06	222.94	179.25	271.41	347.52
Book Value Per Share	5.96	2.81	3.02	3.49	5.75	13.90
Tangible Book Value	521.92	233.06	222.94	179.25	271.41	347.52
Tangible Book Value Per Share	5.96	2.81	3.02	3.49	5.75	13.90

SEC Filings: 10-K · 10-Q